Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284978 | 0.87 | NPC1 (0.60) | CFDKDM4EPTPN2PTPN1ABCC1 | |
| SCHEMBL1285296 | 0.87 | RAB9A (0.56) | CFDKDM4EPTPN2PTPN1LMNA | |
| SCHEMBL1285291 | 0.87 | MEN1 (0.60) | KDM4EPTPN2PTPN1ABCC1ALDH1A1 | |
| SCHEMBL288368 | 0.87 | HTT (0.56) | PTPN2PTPN1MAPK8MAPK10ALDH1A1 | |
| SCHEMBL1285534 | 0.86 | EPHX1 (0.51) | KDM4EPTPN2PTPN1ABCC1MAPK8 | |
| SCHEMBL1285726 | 0.83 | MEN1 (0.62) | KDM4EGSK3BPTPN2PTPN1LMNA | |
| SCHEMBL1285277 | 0.83 | KMT2A (0.61) | KDM4EPTPN2PTPN1LMNAABCC1 | |
| SCHEMBL1285222 | 0.80 | ABCC1 (0.63) | KDM4EPTPN2PTPN1LMNAABCC1 | |
| SCHEMBL1285621 | 0.78 | CASR (0.60) | PTPN2PTPN1ABCC1ALDH1A1 | |
| SCHEMBL1286239 | 0.78 | KMT2A (0.60) | KDM4EGSK3BMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023200017-A1 | NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-10-19 | — | — | WO | disclosed |
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2427451-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BioLab Corporation (JP) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CFD 4299/4885KDM4E 4005/4885GSK3B 1422/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CFD 4299/4885KDM4E 4005/4885GSK3B 1422/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CFD 4299/4885KDM4E 4005/4885GSK3B 1422/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | CFD 4299/4885KDM4E 4005/4885GSK3B 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.